Roche Holding AG (RHHBY) on Monday announced positive data from Phase 3 Portal study, a long-term extension of the Phase III Archway study, of Susvimo for the treatment of people with neovascular age-related macular degeneration (nAMD).
Results showed that with two refills a year, Susvimo maintained vision and stabilised the retina for five years, with durability maintained in about 95% of patients.
The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.